Product nameAnti-Complement C9 antibody [EPR11232-82]
See all Complement C9 primary antibodies
DescriptionRabbit monoclonal [EPR11232-82] to Complement C9
Tested applicationsSuitable for: WB, IHC-Pmore details
Unsuitable for: IP
Species reactivityReacts with: Human
Does not react with: Mouse, Rat
Recombinant fragment within Human Complement C9. The exact sequence is proprietary.
Database link: P02748
- WB: Human serum lysates; IHC-P: human colon and spleen tissue.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab173302 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 72 kDa (predicted molecular weight: 63 kDa).|
For unpurified use at 1/100 - 1/200.
FunctionConstituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC.
Involvement in diseaseDefects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis.
Sequence similaritiesBelongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 1 TSP type-1 domain.
modificationsThrombin cleaves factor C9 to produce C9a and C9b.
Phosphorylation sites are present in the extracelllular medium.
Cellular localizationSecreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore.
- Information by UniProt
- C9 antibody
- CO9_HUMAN antibody
- Complement component C9b antibody
Anti-Complement C9 antibody [EPR11232-82] (ab173302) at 1/10000 dilution (Purified) + Human serum lysates at 15 µg
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 63 kDa
Observed band size: 60-70 kDa why is the actual band size different from the predicted?
The molecular weight observed is consistent with what has been described in PMID: 29767720
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human colon tissue sections labeling Complement C9 with purified ab173302 at 1/10,000 dilution (0.07 µg/ml). Heat mediated antigen retrieval was performed Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
Immunohistochemical analysis of paraffin embedded Human colon tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.
Immunohistochemical analysis of paraffin embedded Human spleen tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.
This product has been referenced in:
- Deleon-Pennell KY et al. Glycoproteomic Profiling Provides Candidate Myocardial Infarction Predictors of Later Progression to Heart Failure. ACS Omega 4:1272-1280 (2019). Read more (PubMed: 30729226) »
- Zhao P et al. The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer. BMC Cancer 19:201 (2019). Read more (PubMed: 30841875) »